BMS says Phase III trials for Opdivo show improved overall survival in lung cancer
Bristol-Myers Squibb (NYSE:BMY) said late-stage trials for its immuno-therapy Opdivo (nivolumab) showed improved overall survival in lung cancer at the two-year time point.
The trials were to evaluate overall survival via two pivotal Phase III studies versus docetaxel in previously treated metastatic non-small cell lung cancer (NSCLC). In addition, the safety profile of Opdivo at two years was consistent with previous reports of data from both studies.
Hossein Borghaei, chief, Thoracic Oncology, Fox Chase Cancer Center, said: “Data presented at ASCO underscore the potential of Opdivo to improve long-term outcomes for patients with this particularly challenging disease.”
Nick Botwood development lead, Lung and Head & Neck, Bristol-Myers Squibb, said: “Today, these data from CheckMate -057 and -017 expand our understanding of the potential for Opdivo to provide a meaningful, durable survival benefit to patients with previously treated metastatic NSCLC.”
Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved …
Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based …